Policy perspective reports guidance on real-world evidence sources in clinical populations, highlighting new regulatory pathways for evaluating drug and medical device safety.
The FDA is developing guidance on the use of “real-world evidence” — health care information from atypical sources, including electronic health records, billing databases, and product and disease registries — to assess the safety and effectiveness of drugs and devices.
No takes yet. Share an insight, caveat, or question.
Sherman et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: